Beyond QMSR Compliance: Why FDA's Updated Quality Framework Requires a More Integrated Approach to Medical Device Operations
The implementation of FDA's Quality Management System Regulation (QMSR) represents an important milestone in the evolution of medical device quality management in the United States.
Effective February 2, 2026, the QMSR amended 21 CFR Part 820 by incorporating ISO 13485:2016 by reference, bringing FDA's medical device quality management requirements into closer alignment with internationally recognized practices. For medical device manufacturers, however, the significance of this change extends beyond updating procedures or aligning documentation with a revised regulatory framework.
The real challenge is ensuring that quality management processes are effectively integrated across product development, supplier management, manufacturing, validation, change control, and post-market activities. With FDA's updated inspection process now in effect, organizations have an opportunity to evaluate not only whether their quality systems meet applicable requirements, but also how consistently those systems support operational decisions and product quality throughout the device lifecycle.
Understanding the QMSR Regulatory Framework
FDA's QMSR incorporates ISO 13485:2016 into the agency's current good manufacturing practice requirements for medical devices. The regulation maintains FDA-specific requirements and clarifications, meaning that alignment with ISO 13485 alone does not automatically establish full compliance with all applicable U.S. regulatory obligations. The purpose of the updated framework is to promote greater international harmonization while maintaining FDA's expectations for the safety, effectiveness, and quality of medical devices.
For manufacturers operating across multiple markets, this alignment may support a more consistent approach to quality management. However, companies must still account for applicable jurisdiction-specific requirements, regulatory responsibilities, and product-related obligations. A quality system that is effectively implemented should connect regulatory requirements with the activities that influence product development, manufacturing, and ongoing product performance.
FDA's Updated Inspection Process
One of the most significant operational changes accompanying QMSR implementation is FDA's transition to a revised medical device inspection process.
On February 2, 2026, FDA discontinued the Quality System Inspection Technique (QSIT) and began using the inspection process described in Compliance Program 7382.850.
This change makes it important for manufacturers to understand how their quality management systems may be evaluated under the updated inspection framework.
Inspection readiness should not be limited to preparing documents when an inspection is anticipated. It depends on maintaining accurate records, consistently executing established processes, and demonstrating that quality activities are functioning as intended.
For example, supplier qualification records, process validation documentation, corrective and preventive action investigations, and change control assessments should reflect actual operational practices. When documentation and execution become disconnected, organizations may struggle to demonstrate effective control, even when individual procedures appear comprehensive.
Connecting Quality Management With Product Development
Quality management begins long before a medical device enters commercial production.
Design and development activities establish requirements, identify potential risks, generate verification and validation evidence, and define the characteristics that must be controlled throughout manufacturing. Under an integrated quality management approach, these activities should remain connected as products move from development into production and through subsequent lifecycle changes.
A design modification, for example, may affect manufacturing specifications, supplier requirements, risk management documentation, process validation, labeling, or regulatory submissions. Evaluating such changes requires more than updating a drawing or approving an engineering change order. Organizations need mechanisms for assessing the broader implications across affected functions. Early collaboration among Regulatory Affairs, Quality, R&D, Manufacturing, and Program Management can help identify these dependencies and reduce the risk of discovering significant gaps late in development or during commercialization.
Supplier Management and Manufacturing Controls
Medical device manufacturers increasingly rely on complex supplier networks, specialized manufacturing processes, and multiple production locations. Maintaining effective control across these activities requires clear responsibilities, appropriate supplier evaluation, defined acceptance criteria, and ongoing monitoring of supplier performance. A supplier change may appear straightforward from a procurement perspective but introduce important considerations for product quality, material equivalence, manufacturing performance, or process validation.
Similarly, manufacturing process adjustments may require evaluation of their potential impact on established process controls, product specifications, and validated conditions.
An effective quality management system should provide a structured approach to assessing these changes and documenting the rationale for decisions. This is particularly important during technology transfers, production scale-up, and the introduction of new manufacturing equipment or processes. Quality and operational teams should work together to ensure that regulatory expectations are reflected in practical manufacturing controls.
Validation as an Operational and Quality Management Activity
Validation is another area where the connection between regulatory compliance and operational execution becomes especially important. Manufacturers must establish appropriate evidence that processes requiring validation can consistently achieve their intended results. This requires careful consideration of process characteristics, potential sources of variability, acceptance criteria, equipment capabilities, monitoring strategies, and the conditions under which manufacturing activities are performed.
Validation should not be treated solely as a collection of protocols and reports prepared to satisfy documentation requirements. It is a mechanism for establishing confidence in manufacturing processes and identifying conditions that could affect product quality. When validation activities are planned independently from product development, manufacturing readiness, and change management, organizations may encounter delays, repeated testing, or unexpected gaps in supporting evidence. Integrating validation planning into the broader development and manufacturing strategy can help teams coordinate resources, recognize critical dependencies, and make informed decisions as programs progress.
The Role of Risk Management and CAPA
Risk-based decision-making is fundamental to effective medical device quality management.
Organizations need to understand how risks identified during development, manufacturing, and post-market activities influence the controls established throughout the product lifecycle.
Corrective and preventive action (CAPA) processes provide an important mechanism for identifying quality problems, investigating causes, implementing appropriate actions, and evaluating their effectiveness. However, CAPA effectiveness depends on more than completing investigations and closing records. Information generated through complaints, non-conformances, supplier performance monitoring, manufacturing trends, and other quality activities should inform decisions about whether existing controls remain adequate.
When these processes operate independently, organizations may miss opportunities to identify recurring issues or emerging risks.
A connected quality management approach enables information from different parts of the organization to contribute to a more complete understanding of product and process performance.
Why Cross-Functional Program Execution Matters
One of the recurring challenges in medical device organizations is that regulatory compliance activities are often managed across multiple functional teams.
Regulatory Affairs may focus on submission requirements and regulatory impact assessments. Quality oversees quality management processes and compliance. R&D manages design activities, while Manufacturing and Operations focus on process readiness, production performance, and supply continuity. Each function has important responsibilities, but the dependencies between them can create significant execution challenges.
For example, a process validation delay may affect production readiness, product availability, regulatory commitments, or commercialization milestones. A supplier qualification issue may influence manufacturing schedules and require additional technical or quality assessments. Without coordinated planning, these dependencies may become visible only after they begin affecting program timelines. Effective program management helps connect these activities by establishing clear responsibilities, tracking critical deliverables, maintaining visibility of risks, and supporting timely cross-functional decisions. This coordination becomes particularly valuable during quality system improvements, manufacturing transfers, new product introductions, and major operational changes.
What Medical Device Manufacturers Should Consider
With the QMSR now effective, manufacturers should consider whether their quality management systems are operating consistently across the functions and sites involved in the product lifecycle. This includes evaluating whether quality processes reflect current requirements, whether responsibilities are clearly established, and whether records demonstrate consistent execution.
Organizations should also examine the connections between supplier controls, development activities, manufacturing processes, validation, CAPA, and change management. The objective is not simply to increase documentation. It is to ensure that documentation, operational practices, and quality decisions remain aligned.
A well-integrated quality management system can support inspection readiness while also helping organizations manage complexity, reduce avoidable rework, and maintain appropriate control as products and manufacturing operations evolve.
Turning Regulatory Compliance Into Operational Excellence
FDA's implementation of the QMSR marks an important step toward greater international alignment in medical device quality management.
For manufacturers, the transition also reinforces the importance of treating quality as an integral part of product development and operational execution.
Meeting regulatory requirements remains essential. Equally important is ensuring that quality management activities are effectively connected across the organization and that teams can demonstrate consistent control throughout the product lifecycle.
The organizations best positioned to manage this complexity are those that translate regulatory requirements into practical processes, coordinated responsibilities, and informed decisions.
Ultimately, effective quality management is not only about inspection readiness. It is about establishing the operational discipline necessary to support reliable manufacturing, product quality, and continued regulatory compliance.
About OneGlobal Trinity M Consulting
OneGlobal Trinity M Consulting supports medical device, pharmaceutical, and biotechnology organizations navigating complex regulatory, quality, clinical, product development, validation, and program execution challenges.
We work with organizations to connect strategy with execution, helping cross-functional teams align regulatory requirements, development activities, evidence needs, project timelines, risks, and key decisions throughout the product lifecycle. Our experience across global life sciences programs enables us to support organizations as they navigate evolving regulatory expectations, complex development initiatives, and the operational challenges associated with bringing products to market.
Contact us to learn more about how OneGlobal Trinity M Consulting can support your organization.
References
U.S. Food and Drug Administration. Quality Management System Regulation (QMSR). Updated February 2, 2026. https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
U.S. Food and Drug Administration. Quality and Compliance (Medical Devices). Updated February 2, 2026. https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/quality-and-compliance-medical-devices
U.S. Food and Drug Administration. Town Hall: FDA's Quality Management System Regulation (QMSR): Medical Device Risk-Based Inspections. April 1, 2026. https://www.fda.gov/medical-devices/medical-devices-news-and-events/town-hall-fdas-quality-management-system-regulation-qmsr-medical-device-risk-based-inspections
Regulatory note: The QMSR became effective February 2, 2026. It incorporates ISO 13485:2016 by reference while retaining applicable FDA-specific requirements. Manufacturers should evaluate their obligations based on the regulation, the scope of their activities, and applicable FDA requirements.




Comments